Gender	Male
E-mail	savio.woo@mssm.edu
	oneida.cintron@mssm.edu
Education and Training	Ph.D., University of Washington
	B.S, Loyola College
	Postdoctorate, University of British Columbia
Awards	2008 Advancement of Cancer Research Award For the development of immune-modulatory therapy and oncolytic virotherapy for cancers Gilda's Club NYC
	2000 Researcher of the Year Award For the cloning of the factor IX gene and its use in correcting the genetic disorder in affected animals by gene therapy National Hemophilia Foundation
	1989 Research and Development Award For the cloning of the PKU gene and development of a procedure for prenatal diagnosis of the genetic disorder UNICEF
	1988 - 1998 MERIT Award For the cloning of the PKU gene and the molecular characterization of major disease-causing mutations in the Caucasians and Orientals National Institute of Child Health and Human Development
	1983 Noel Rain Memorial Award For the cloning and characterization of several human genes involved in metabolic disorders The Society for the Study of Inborn Errors of Metabolism

Professor and Founding Chairman of the Department of Gene and Cell Medicine

Woo Laboratory

Education and Training	Ph.D., University of Washington
	B.S, Loyola College
	Postdoctorate, University of British Columbia

Immune-modulatory gene therapy for metastatic cancer
A combination of intratumoral administration of a recombinant adenovirus expressing interleukin-12 and intraperitoneal injection of a 4-1BB activation protein has been shown to be effective and safe in the treatment of metastatic colorectal and breast cancers in mice. The novel treatment developed in the ;laboratory has advanced to clinical translation and there are ongoing clinical trials at Mount Sinai for these disease indications.

Oncolytic VSV Virotherapy for Liver Cancer
Intravascular administration of a replication competent Vesicular Stomititis Virus expressing a viral chemokine binding protein gene has been shown to effectively destroy multi-focal lesions of Hepatocellular Carcinoma in the liver of rats, which led to substantial survival prolongation and tumor rejection in half of the animals. Preclinical pharmacology and toxicology studies are being performed to support an Investigative New Drug application with the FDA, and a clinical trial for patients with advanced liver cancer will be initiated in 2010.  

Xu D, Sauter B, Huang T, Meseck M, Woo SC, Chen S. Systemic Administration of Ig-4-1BB Ligand in Combination with IL-12 Gene Transfer Eradicates Hepatic Colon Carcinoma. Gene Therapy 2005; 12: 1526-1533.

Chen L, Huang TG, Meseck M, Mandeli J, Fallon J, Woo SC. Rejection of meatstatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. Mol. Ther 2007; 15: 2194-2202.

Altomonte J, Wu L, Meseck M, Ebert O, Garcia-Sastre A, Fallon J, Woo SL. Exponential Enhancement of Oncolytic VSV Potency by Vector Mediated Suppression of Inflammatory Responses In Vivo . Mol. Ther 2008; 16: 146-153.

Wu L, Huang TG, Meseck M, Altomonte J, Ebert O, Shinzaki K, Garcia-Sastre A, Fallon J, Mandeli J, Woo SC. rVSV(Mdelta51)-M3 is an Effective and Safe Oncolytic Virus for Cancer Therapy. Human Gene Therapy 2008; 19: 635-647.

Li Z, Fallon J, Mandeli J, Wetmur J, Woo SC. A genetically Enhanced Anaerobic Bacterium for Oncopathic Therapy of Pancreatic Cancer. J. Natl. Can. Inst 2008; 100: 1389-1400.